Compare MIND & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIND | CING |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.4M | 93.1M |
| IPO Year | N/A | N/A |
| Metric | MIND | CING |
|---|---|---|
| Price | $6.45 | $5.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | 201.5K | ★ 394.5K |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.51 | $3.20 |
| 52 Week High | $14.50 | $11.89 |
| Indicator | MIND | CING |
|---|---|---|
| Relative Strength Index (RSI) | 39.33 | 41.87 |
| Support Level | N/A | $4.94 |
| Resistance Level | $9.22 | $6.85 |
| Average True Range (ATR) | 0.47 | 0.44 |
| MACD | -0.20 | 0.02 |
| Stochastic Oscillator | 19.18 | 24.34 |
MIND Technology Inc provides technology and solutions for exploration, survey, and defense applications in oceanographic, hydrographic, defense, seismic, and security industries. The company operates in segments namely, Seamap Marine Products and Klein Marine Products helps manufacture and sell specialized, high-performance sonar and seismic equipment. The company generates more revenue from Seamap Marine Products. The company's geographical segments include the United States; China, Norway; Turkey; Singapore; and Canada & Other.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.